[go: up one dir, main page]

WO2012030050A3 - 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 - Google Patents

퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 Download PDF

Info

Publication number
WO2012030050A3
WO2012030050A3 PCT/KR2011/003669 KR2011003669W WO2012030050A3 WO 2012030050 A3 WO2012030050 A3 WO 2012030050A3 KR 2011003669 W KR2011003669 W KR 2011003669W WO 2012030050 A3 WO2012030050 A3 WO 2012030050A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
prevention
treatment
pharmaceutical composition
brain disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/003669
Other languages
English (en)
French (fr)
Other versions
WO2012030050A2 (ko
WO2012030050A9 (ko
Inventor
서유헌
코폴라수수르타
노수진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Braintropia Co Ltd
Original Assignee
Braintropia Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braintropia Co Ltd filed Critical Braintropia Co Ltd
Priority to US13/820,520 priority Critical patent/US9040580B2/en
Priority to JP2013526989A priority patent/JP5852653B2/ja
Priority to AU2011296802A priority patent/AU2011296802B2/en
Priority to EP11822025.0A priority patent/EP2612668A4/en
Priority to CN201180042607.0A priority patent/CN103079556B/zh
Publication of WO2012030050A2 publication Critical patent/WO2012030050A2/ko
Publication of WO2012030050A3 publication Critical patent/WO2012030050A3/ko
Publication of WO2012030050A9 publication Critical patent/WO2012030050A9/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물에 관한 것으로, 보다 상세하게는 활성산소를 제거하는 항산화, 세포사멸 억제, 운동장애 개선과 감퇴된 기억력 증진에 유용한 효과가 있는 유효성분인 파라벤 화합물을 함유하는, 파킨슨병, 알츠하이머 치매(노인성 치매), 뇌졸중, 루게릭병, 픽크병, 크로이츠펠트 야콥병, 헌팅톤병, 진행성 핵상마비, 척수소뇌 변성증, 소뇌 위축증, 다발성 경화증, 외상 후 스트레스 장애, 기억상실증 등의 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물에 관한 것이다.
PCT/KR2011/003669 2010-09-03 2011-05-18 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 Ceased WO2012030050A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/820,520 US9040580B2 (en) 2010-09-03 2011-05-18 Method for prevention or treatment of degenerative neurologial brain disorders
JP2013526989A JP5852653B2 (ja) 2010-09-03 2011-05-18 退行性神経系脳疾患の予防又は治療用薬剤
AU2011296802A AU2011296802B2 (en) 2010-09-03 2011-05-18 Pharmaceutical composition for prevention or treatment of degenerative neurological brain disorders
EP11822025.0A EP2612668A4 (en) 2010-09-03 2011-05-18 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE NEUROLOGICAL CEREBRAL DISORDERS
CN201180042607.0A CN103079556B (zh) 2010-09-03 2011-05-18 一种用于预防或治疗神经退行性脑功能紊乱的药物组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100086280A KR101196354B1 (ko) 2010-09-03 2010-09-03 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
KR10-2010-0086280 2010-09-03

Publications (3)

Publication Number Publication Date
WO2012030050A2 WO2012030050A2 (ko) 2012-03-08
WO2012030050A3 true WO2012030050A3 (ko) 2012-04-26
WO2012030050A9 WO2012030050A9 (ko) 2012-06-14

Family

ID=45773334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/003669 Ceased WO2012030050A2 (ko) 2010-09-03 2011-05-18 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물

Country Status (7)

Country Link
US (1) US9040580B2 (ko)
EP (1) EP2612668A4 (ko)
JP (1) JP5852653B2 (ko)
KR (1) KR101196354B1 (ko)
CN (1) CN103079556B (ko)
AU (1) AU2011296802B2 (ko)
WO (1) WO2012030050A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
CN105250545A (zh) * 2015-10-16 2016-01-20 卢仁华 一种卢伽雷氏症治疗药物
KR101885224B1 (ko) * 2016-05-26 2018-09-11 대봉엘에스 주식회사 금불초, 삼지구엽초 및 마디풀 복합 추출물 제조방법, 및 이로부터 제조된 기능성 화장료 조성물
IL263494B2 (en) * 2016-06-13 2024-01-01 Syneurx Int Taiwan Corp Use of lithium benzoate for treating central nervous system disorders
KR102775989B1 (ko) 2022-11-01 2025-03-04 윤주호 콜치신과 메트포르민을 유효성분으로 하는 퇴행성 신경계 질환의 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020084311A (ko) * 2001-04-25 2002-11-07 (주) 디지탈바이오텍 진세노사이드 가수분해물을 함유하는 퇴행성 뇌질환의예방 및 치료용 조성물
KR20050062574A (ko) * 2002-10-01 2005-06-23 가부시키가이샤 우에노 세이야꾸 오요 겡뀨조 히드록시벤조산류의 제조방법
KR20070092497A (ko) * 2006-03-10 2007-09-13 학교법인 한림대학교 삼지구엽초 추출물을 포함하는 허혈성 뇌혈관질환 예방또는 개선용 조성물
KR20090048934A (ko) * 2007-11-12 2009-05-15 강원도 메틸파라하이드록시벤조에이트를 유효성분으로 함유하는제초제 조성물 및 삼지구엽초로부터메틸파라하이드록시벤조에이트의 분리방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779500T2 (de) * 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide
DE69936640D1 (de) * 1998-04-21 2007-09-06 Us Health Cannabinoiden als antioxidantien und neuroschützende mittel
KR100535655B1 (ko) * 2003-03-14 2005-12-08 충남대학교산학협력단 신경세포 보호 효과 및 항산화 활성을 갖는 머위 추출물
US20050244502A1 (en) * 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method
EP1796635A2 (en) * 2004-09-14 2007-06-20 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
AU2007341356B2 (en) * 2006-12-28 2013-08-29 F. Hoffmann-La Roche Ag Crystalline forms Glyt1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020084311A (ko) * 2001-04-25 2002-11-07 (주) 디지탈바이오텍 진세노사이드 가수분해물을 함유하는 퇴행성 뇌질환의예방 및 치료용 조성물
KR20050062574A (ko) * 2002-10-01 2005-06-23 가부시키가이샤 우에노 세이야꾸 오요 겡뀨조 히드록시벤조산류의 제조방법
KR20070092497A (ko) * 2006-03-10 2007-09-13 학교법인 한림대학교 삼지구엽초 추출물을 포함하는 허혈성 뇌혈관질환 예방또는 개선용 조성물
KR20090048934A (ko) * 2007-11-12 2009-05-15 강원도 메틸파라하이드록시벤조에이트를 유효성분으로 함유하는제초제 조성물 및 삼지구엽초로부터메틸파라하이드록시벤조에이트의 분리방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2612668A4 *

Also Published As

Publication number Publication date
KR101196354B1 (ko) 2012-11-01
JP2013536258A (ja) 2013-09-19
CN103079556A (zh) 2013-05-01
WO2012030050A2 (ko) 2012-03-08
JP5852653B2 (ja) 2016-02-03
CN103079556B (zh) 2015-05-13
EP2612668A2 (en) 2013-07-10
US9040580B2 (en) 2015-05-26
US20130178527A1 (en) 2013-07-11
AU2011296802B2 (en) 2014-09-25
AU2011296802A1 (en) 2013-04-11
WO2012030050A9 (ko) 2012-06-14
EP2612668A4 (en) 2014-03-19
KR20120023352A (ko) 2012-03-13

Similar Documents

Publication Publication Date Title
WO2012030050A3 (ko) 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
MX2009012163A (es) Hetarilanilinas como moduladores para beta-amiloide.
WO2008130449A3 (en) Modulators of amyloid-beta production
MY178156A (en) Compounds and their use as bace inhibitors
WO2012082718A3 (en) 3-methanesulfonylpropionitrile for treating inflammation and pain
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
WO2010037135A3 (en) Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2008157425A3 (en) Compounds for inhibiting protein aggregation, and methods for making and using them
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
WO2010077068A3 (en) Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same
IL190710A0 (en) Diuretic-like compound analogs and pharmaceutical compositions for regulation of central nervous system disorders containing the same
TW200745003A (en) Novel compounds
MY148899A (en) Fast dissociating dopamine 2 receptor antagonists
WO2010127143A3 (en) Neuroprotective ganoderma compositions and methods of use
EP2609914A8 (en) Novel methods for treating or preventing neurodegeneration
WO2011023367A3 (en) Bisphosphonate-prodrugs
SG10201907289VA (en) Monomethylfumarate prodrug compositions
WO2008111590A3 (en) Ampa and nmda receptor antagonists for neurodegenerative diseases
NZ592881A (en) Quinolone compound and pharmaceutical composition
UA106907C2 (uk) Стабілізована фармацевтична композиція
MX2012010084A (es) Compuestos utiles para tratar transtornos neurodegenerativos.
WO2008136863A3 (en) Synthesis of compounds useful as modulators of amyloid-beta production
WO2014160940A3 (en) Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180042607.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11822025

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2011822025

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011822025

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013526989

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13820520

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011296802

Country of ref document: AU

Date of ref document: 20110518

Kind code of ref document: A